Free Trial

Perrigo (PRGO) Competitors

Perrigo logo
$16.16 -0.08 (-0.46%)
Closing price 03:59 PM Eastern
Extended Trading
$16.18 +0.02 (+0.12%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PRGO vs. CORT, AXSM, LNTH, AMRX, and BLTE

Should you buy Perrigo stock or one of its competitors? Perrigo's main competitors and comparable companies include Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Perrigo compare to Corcept Therapeutics?

Perrigo (NYSE:PRGO) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

In the previous week, Corcept Therapeutics had 1 more articles in the media than Perrigo. MarketBeat recorded 4 mentions for Corcept Therapeutics and 3 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 0.88 beat Perrigo's score of 0.21 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Perrigo
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Corcept Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Corcept Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.09B0.55-$1.43B-$12.76N/A
Corcept Therapeutics$963.65M7.83$99.65M$1.2754.30

Perrigo presently has a consensus target price of $18.50, suggesting a potential upside of 14.44%. Corcept Therapeutics has a consensus target price of $139.50, suggesting a potential upside of 102.29%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Perrigo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perrigo
2 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.83
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Perrigo has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Corcept Therapeutics has a net margin of 16.53% compared to Perrigo's net margin of -43.27%. Corcept Therapeutics' return on equity of 22.56% beat Perrigo's return on equity.

Company Net Margins Return on Equity Return on Assets
Perrigo-43.27% 12.39% 4.07%
Corcept Therapeutics 16.53%22.56%17.83%

Summary

Corcept Therapeutics beats Perrigo on 13 of the 16 factors compared between the two stocks.

How does Perrigo compare to Axsome Therapeutics?

Perrigo (NYSE:PRGO) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Axsome Therapeutics has lower revenue, but higher earnings than Perrigo. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.09B0.55-$1.43B-$12.76N/A
Axsome Therapeutics$638.50M11.67-$183.17M-$3.06N/A

In the previous week, Axsome Therapeutics had 17 more articles in the media than Perrigo. MarketBeat recorded 21 mentions for Axsome Therapeutics and 4 mentions for Perrigo. Axsome Therapeutics' average media sentiment score of 0.22 beat Perrigo's score of 0.21 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Perrigo
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Axsome Therapeutics
3 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

95.9% of Perrigo shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Axsome Therapeutics has a net margin of -18.18% compared to Perrigo's net margin of -43.27%. Perrigo's return on equity of 12.39% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Perrigo-43.27% 12.39% 4.07%
Axsome Therapeutics -18.18%-198.73%-22.03%

Perrigo presently has a consensus price target of $18.50, indicating a potential upside of 14.03%. Axsome Therapeutics has a consensus price target of $266.21, indicating a potential upside of 87.88%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Perrigo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perrigo
2 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.83
Axsome Therapeutics
1 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.86

Perrigo has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Summary

Axsome Therapeutics beats Perrigo on 12 of the 17 factors compared between the two stocks.

How does Perrigo compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Perrigo (NYSE:PRGO) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, Lantheus had 2 more articles in the media than Perrigo. MarketBeat recorded 6 mentions for Lantheus and 4 mentions for Perrigo. Lantheus' average media sentiment score of 0.87 beat Perrigo's score of 0.21 indicating that Lantheus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Perrigo
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lantheus has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 0.4% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lantheus has a net margin of 17.28% compared to Perrigo's net margin of -43.27%. Lantheus' return on equity of 29.26% beat Perrigo's return on equity.

Company Net Margins Return on Equity Return on Assets
Lantheus17.28% 29.26% 15.40%
Perrigo -43.27%12.39%4.07%

Lantheus has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantheus$1.54B4.31$233.56M$4.0625.02
Perrigo$4.09B0.55-$1.43B-$12.76N/A

Lantheus presently has a consensus target price of $107.44, indicating a potential upside of 5.76%. Perrigo has a consensus target price of $18.50, indicating a potential upside of 14.03%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Lantheus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.21
Perrigo
2 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.83

Summary

Lantheus beats Perrigo on 13 of the 16 factors compared between the two stocks.

How does Perrigo compare to Amneal Pharmaceuticals?

Perrigo (NYSE:PRGO) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

95.9% of Perrigo shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 0.4% of Perrigo shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Amneal Pharmaceuticals has a net margin of 4.17% compared to Perrigo's net margin of -43.27%. Amneal Pharmaceuticals' return on equity of 283.50% beat Perrigo's return on equity.

Company Net Margins Return on Equity Return on Assets
Perrigo-43.27% 12.39% 4.07%
Amneal Pharmaceuticals 4.17%283.50%7.79%

Amneal Pharmaceuticals has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.09B0.55-$1.43B-$12.76N/A
Amneal Pharmaceuticals$3.02B2.47$72.06M$0.4250.90

Perrigo currently has a consensus price target of $18.50, indicating a potential upside of 14.03%. Amneal Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 7.58%. Given Perrigo's higher probable upside, equities analysts plainly believe Perrigo is more favorable than Amneal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perrigo
2 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.83
Amneal Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

Perrigo has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market.

In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than Perrigo. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 4 mentions for Perrigo. Amneal Pharmaceuticals' average media sentiment score of 0.38 beat Perrigo's score of 0.21 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Perrigo
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amneal Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Amneal Pharmaceuticals beats Perrigo on 13 of the 16 factors compared between the two stocks.

How does Perrigo compare to Belite Bio?

Perrigo (NYSE:PRGO) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

In the previous week, Belite Bio had 16 more articles in the media than Perrigo. MarketBeat recorded 20 mentions for Belite Bio and 4 mentions for Perrigo. Belite Bio's average media sentiment score of 0.60 beat Perrigo's score of 0.21 indicating that Belite Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Perrigo
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Belite Bio
2 Very Positive mention(s)
6 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Belite Bio has lower revenue, but higher earnings than Perrigo. Belite Bio is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.09B0.55-$1.43B-$12.76N/A
Belite BioN/AN/A-$77.61M-$2.73N/A

Perrigo currently has a consensus target price of $18.50, indicating a potential upside of 14.03%. Belite Bio has a consensus target price of $226.27, indicating a potential upside of 37.68%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts plainly believe Belite Bio is more favorable than Perrigo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Perrigo
2 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.83
Belite Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67

Belite Bio has a net margin of 0.00% compared to Perrigo's net margin of -43.27%. Perrigo's return on equity of 12.39% beat Belite Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Perrigo-43.27% 12.39% 4.07%
Belite Bio N/A -9.95%-9.76%

Perrigo has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.19, meaning that its share price is 219% less volatile than the broader market.

Summary

Belite Bio beats Perrigo on 9 of the 15 factors compared between the two stocks.

Get Perrigo News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRGO vs. The Competition

MetricPerrigoPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$2.24B$13.76B$7.83B$23.18B
Dividend Yield7.17%2.58%2.47%3.78%
P/E Ratio-1.2729.0834.3229.41
Price / Sales0.557.748.003.24
Price / Cash3.0715.7421.0215.64
Price / Book0.765.194.764.04
Net Income-$1.43B$2.88B$3.52B$1.08B
7 Day Performance-4.86%-3.90%-5.35%-3.09%
1 Month Performance-2.51%-3.99%-3.62%-1.21%
1 Year Performance17.43%-7.16%-0.62%5.64%

Perrigo Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRGO
Perrigo
2.0229 of 5 stars
$16.17
-0.5%
$18.50
+14.4%
+17.9%$2.24B$4.09BN/A8,100
CORT
Corcept Therapeutics
4.0532 of 5 stars
$75.03
+3.1%
$139.50
+85.9%
-3.4%$8.67B$761.41M62.38730
AXSM
Axsome Therapeutics
3.5532 of 5 stars
$133.96
+1.2%
$267.58
+99.7%
+1.4%$7.21B$638.50MN/A925
LNTH
Lantheus
2.4698 of 5 stars
$101.01
+0.4%
$107.44
+6.4%
+91.6%$6.60B$1.54B20.311,193
AMRX
Amneal Pharmaceuticals
3.5351 of 5 stars
$21.28
+5.7%
$23.00
+8.1%
+83.7%$6.37B$3.02B50.678,500

Related Companies and Tools


This page (NYSE:PRGO) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners